



Practitioner's Docket No. MBIO1997-018DV1ACN1(M)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: MBIO1997-018DV1ACN1(M)

Application No.: 09/993,179

Group No.: 1636

Filed: November 6, 2001

Examiner:

For: SECRETED PROTEINS AND NUCLEIC ACIDS ENCODING THEM

Inventors: Sean A. McCarthy et al.

U.S Patent and Trademark Office

Box Sequence, P.O. Box 2327

Arlington, VA 22202

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
AND/OR AMENDMENT PERTAINING THERETO
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE


Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

January 30, 2002

Date of Signature and of Mail Deposit

By:


Sean Hunziker

1. This replies to the Office Communication including a Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated January 3, 2002. This response corrects the errors noted in the Raw Sequence Listing Error Report which accompanied the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

A copy of the Notice to Comply with Requirements for patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures and a copy of the Raw Sequence Listing Error Report is enclosed.

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, Jean M. Silveri state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith are:

Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.

each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.

nt that the content of each "Sequence Listing" submitted and each computer readable are the same, as required in 37 C.F.R. Section 1.821(g).

his submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), ment that the submission includes no new matter.

**STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
FOR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

uter readable form submitted in this application, including those forms requested to be red from applicant's other application, is the same as the "Sequence Listing" to which it ated to relate.

accompanying this submission, or for which a request for transfer from applicants' other tion, introduce no new matter.

STATUS

er than a small entity.

MILLENNIUM PHARMACEUTICALS, INC.


SIGNATURE OF PRACTITIONER

Jean M. Silveri
Reg. No. 39,030
75 Sidney Street
Cambridge, MA 02139
Tel. No.: (617) 679-7336
Facsimile: (617) 551-8820



COPY

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/993,179	11/06/2001	Sean A. McCarthy	MBIO1997-018DV1ACN1 (M)

CONFIRMATION NO. 1059

FORMALITIES LETTER



OC000000007254847

Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, MA 02139

Date Mailed: 01/03/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY